In addition to being one of the first models to include KRAS mutation status as a surrogate of tumor biology, the GAME score differentiates itself from the previous models by incorporating the tumor burden score (TBS), a redefined CEA level (20 ng/mL) and extrahepatic disease [21]. This evidence concerns the gene KRAS and neoplasm.